PURPOSE: Study distribution, pharmacokinetics, and safety of intraperitoneal (IP) 212Pb-TCMC-trastuzumab in patients with HER-2-expressing malignancy. EXPERIMENTAL DESIGN: IP 212Pb-TCMC-trastuzumab was delivered, after 4 mg/kg intravenous (IV) trastuzumab, to 3 patients with HER-2-expressing cancer who had failed standard therapies. Patients were monitored for toxicity and pharmacokinetics/dosimetry parameters. RESULTS: Imaging studies after 0.2 mCi/m2 (7.4 MBq/m2) show little redistribution out of the peritoneal cavity and no significant uptake in major organs. Peak blood level of the radiolabeled antibody, determined by decay corrected counts, was <23% injected dose at 63 hours; maximum blood radioactivity concentration was 6.3nCi/mL at 18 hours. Cumulative urinary excretion was ≤6% in 2.3 half-lives. The maximum external exposure rate immediately post-infusion at skin contact over the abdomen averaged 7.67 mR/h and dropped to 0.67 mR/h by 24 hours. The exposure rates at the other positions monitored (axilla, chest, and femur) decreased as a function of distance from the abdomen. The data points correlate closely with 212Pb physical decay (T1/2=10.6 hours). Follow-up >6 months showed no evidence of agent-related toxicity. CONCLUSIONS: Pharmacokinetics and imaging after 0.2 mCi/m2 IP 212Pb-TCMC-trastuzumab in patients with HER-2-expressing malignancy showed minimal distribution outside the peritoneal cavity, ≤6% urinary excretion, and good tolerance.
PURPOSE: Study distribution, pharmacokinetics, and safety of intraperitoneal (IP) 212Pb-TCMC-trastuzumab in patients with HER-2-expressing malignancy. EXPERIMENTAL DESIGN:IP 212Pb-TCMC-trastuzumab was delivered, after 4 mg/kg intravenous (IV) trastuzumab, to 3 patients with HER-2-expressing cancer who had failed standard therapies. Patients were monitored for toxicity and pharmacokinetics/dosimetry parameters. RESULTS: Imaging studies after 0.2 mCi/m2 (7.4 MBq/m2) show little redistribution out of the peritoneal cavity and no significant uptake in major organs. Peak blood level of the radiolabeled antibody, determined by decay corrected counts, was <23% injected dose at 63 hours; maximum blood radioactivity concentration was 6.3nCi/mL at 18 hours. Cumulative urinary excretion was ≤6% in 2.3 half-lives. The maximum external exposure rate immediately post-infusion at skin contact over the abdomen averaged 7.67 mR/h and dropped to 0.67 mR/h by 24 hours. The exposure rates at the other positions monitored (axilla, chest, and femur) decreased as a function of distance from the abdomen. The data points correlate closely with 212Pb physical decay (T1/2=10.6 hours). Follow-up >6 months showed no evidence of agent-related toxicity. CONCLUSIONS: Pharmacokinetics and imaging after 0.2 mCi/m2 IP 212Pb-TCMC-trastuzumab in patients with HER-2-expressing malignancy showed minimal distribution outside the peritoneal cavity, ≤6% urinary excretion, and good tolerance.
Authors: Diane E Milenic; Kayhan Garmestani; Erik D Brady; Kwamena E Baidoo; Paul S Albert; Karen J Wong; Joseph Flynn; Martin W Brechbiel Journal: Clin Cancer Res Date: 2008-08-15 Impact factor: 12.531
Authors: René H Verheijen; Leon F Massuger; Benedict B Benigno; Agamemnon A Epenetos; Alberto Lopes; John T Soper; Janica Markowska; Rostislav Vyzula; Tom Jobling; Gordon Stamp; Gregory Spiegel; Dennis Thurston; Theo Falke; Joanna Lambert; Michael V Seiden Journal: J Clin Oncol Date: 2006-02-01 Impact factor: 44.544
Authors: Ronald D Alvarez; Warner K Huh; M B Khazaeli; Ruby F Meredith; Edward E Partridge; Larry C Kilgore; William E Grizzle; Sui Shen; J Max Austin; Mack N Barnes; Delicia Carey; Jeffrey Schlom; Albert F LoBuglio Journal: Clin Cancer Res Date: 2002-09 Impact factor: 12.531
Authors: Emma Y Song; Chang F Qu; Syed M A Rizvi; Chand Raja; Julia Beretov; Alfred Morgenstern; Christos Apostolidis; Frank Bruchertseifer; Alan Perkins; Barry J Allen Journal: Cancer Biol Ther Date: 2007-10-08 Impact factor: 4.742
Authors: A J Jacobs; M Fer; F M Su; H Breitz; J Thompson; H Goodgold; J Cain; J Heaps; P Weiden Journal: Obstet Gynecol Date: 1993-10 Impact factor: 7.661
Authors: Diane E Milenic; Young-Seung Kim; Kwamena E Baidoo; Karen J Wong; Rachel Barkley; Jose Delgado; Martin W Brechbiel Journal: Cancer Biother Radiopharm Date: 2018-06 Impact factor: 3.099
Authors: Mehran Makvandi; Edouard Dupis; Jonathan W Engle; F Meiring Nortier; Michael E Fassbender; Sam Simon; Eva R Birnbaum; Robert W Atcher; Kevin D John; Olivier Rixe; Jeffrey P Norenberg Journal: Target Oncol Date: 2018-04 Impact factor: 4.493
Authors: Benjamin B Kasten; Rebecca C Arend; Ashwini A Katre; Harrison Kim; Jinda Fan; Soldano Ferrone; Kurt R Zinn; Donald J Buchsbaum Journal: Nucl Med Biol Date: 2017-01-10 Impact factor: 2.408
Authors: Sophie Poty; Lukas M Carter; Komal Mandleywala; Rosemery Membreno; Dalya Abdel-Atti; Ashwin Ragupathi; Wolfgang W Scholz; Brian M Zeglis; Jason S Lewis Journal: Clin Cancer Res Date: 2018-10-23 Impact factor: 12.531
Authors: Benjamin B Kasten; Abhishek Gangrade; Harrison Kim; Jinda Fan; Soldano Ferrone; Cristina R Ferrone; Kurt R Zinn; Donald J Buchsbaum Journal: Nucl Med Biol Date: 2017-12-24 Impact factor: 2.408